Figure 5. Pharmacological activation of TRPV4 inhibits EC proliferation in vivo.

(A) Tumors were implanted into C57BL/6 mice by subcutaneously injecting LLC cells. Mice were treated with GSK (+GSK) or saline (−GSK), as previously described¹⁵, and isolated on day 21. Representative images (20X) of the tumor tissue stained with CD31 (red), ki-67 (green), and DAPI (nuclei) were used to quantify the proliferation of TEC. Scale bar = 10 μm (B) Quantitative analysis demonstrating a significant (p ≤ 0.05) decrease in the percentage of proliferating vessels (CD31+ki-67 positive vessels divided by CD31 positive vessels) in tumors treated with GSK (+GSK) compared to untreated tumors (−GSK).